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TOC Tubo-ovarian carcinoma 
BC Breast cancer 
  
RR Relative risk 
CI Confidence interval 
OR Odds ratio 
AIC Akaike information criterion  
LRT Likelihood ratio test 
df Degree of freedom 
PRS Polygenic risk score 








The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma 
(TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C and 
RAD51D. 
Methods 
We analysed data from 6178 families, 125 with pathogenic variants in RAD51C; and 
6690 families, 60 with pathogenic variants in RAD51D. TOC and BC relative and 
cumulative risks were estimated using complex segregation analysis to model the 
cancer inheritance patterns in families, while adjusting for the mode of ascertainment 
of each family. All statistical tests were two-sided. 
Results 
Pathogenic variants in both RAD51C and RAD51D were associated with TOC 
(RAD51C RR=7.55, 95%CI:5.60-10.19, p=5×10-40; RAD51D RR=7.60, 95%CI:5.61-
10.30, p=5×10-39) and BC (RAD51C RR=1.99, 95%CI:1.39-2.85, p=1.55×10-4; 
RAD51D RR=1.83, 95%CI:1.24-2.72, p=0.002). For both RAD51C and RAD51D, 
there was a suggestion that the TOC RRs increased with age until around age 60 
years and decreased thereafter. The estimated cumulative risks of developing TOC to 
age 80 were 11% (95%CI:6-21%) for RAD51C and 13% (95%CI:7-23%) for RAD51D 
pathogenic variant carriers. The estimated cumulative risks of developing BC to 80 
were 21% (95%CI:15-29%) for RAD51C and 20% (95%CI:14-28%) for RAD51D 
pathogenic variant carriers. Both TOC and BC risks for RAD51C/D pathogenic variant 
carriers varied by cancer family history, and could be as high as 32-36% for TOC, for 
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carriers with two first degree relatives diagnosed with TOC; or 44-46% for BC, for 
carriers with two first degree relatives diagnosed with BC.  
Conclusions 
These estimates will facilitate the genetic counselling of RAD51C and RAD51D 
pathogenic variant carriers and justify the incorporation of RAD51C and RAD51D into 




Genetic testing through multi-gene cancer panels is widely available and has 
become an integral part of the genetic counselling and oncologic practice used to 
inform clinical management options. RAD51C and RAD51D are included on widely 
available cancer panels due the reported associations of pathogenic variants in these 
genes with tubo-ovarian carcinoma (TOC) (1). However, the optimal interpretation of 
gene-panel testing results requires precise cancer risk estimates for pathogenic 
variants in RAD51C.  
The reported TOC risks for RAD51C pathogenic variant carriers vary widely 
with odds ratio (OR) estimates ranging from 3.4 to 15.8 based on case-control studies 
and a relative risk (RR) of 5.9 using family-based segregation analysis 
(Supplementary Table 1). Similarly, the reported TOC ORs/RRs for RAD51D 
pathogenic variant carriers ranged from 6.3 to 12.0 (Supplementary Table 1). There 
has been conflicting evidence for the association of both RAD51C and RAD51D 
pathogenic variants with BC risk. Some studies reported an increased BC risk (OR 
estimates for RAD51C:5.9-8.7; RAD51D:3.1-8.3) but others reported no statistically 
significant associations (Supplementary Table 2) (2-4).  
A concern with published risk estimates based on case-control studies, has 
been that cases may have been selected on the basis of cancer family history, which 
may confound the associations and/or lead to an overestimation of cancer risks due 
to the enrichment of cases for pathogenic variants. Furthermore, the pathogenic 
variant frequencies in controls come predominantly from publicly available resources 
and may come from populations that do not closely match the case population. 
Therefore, some of the published risk estimates may be susceptible to selection 
biases or biases due to population stratification and cannot be readily applied in the 
counselling process. Family- or pedigree-based approaches, with appropriate 
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ascertainment corrections in the analysis, which adjust for the ascertainment process 
of each family, address directly such potential biases and can result in more precise 
risk estimates due to the use of information on both genotyped and non-genotyped 
family members. Here, we use a large collection of families with RAD51C and/or 
RAD51D pathogenic variants, to estimate age-specific TOC and BC risks and assess 
how these vary by family history of cancer.  
Methods 
Families 
Families were enrolled between 1996 and 2017 through 28 study centres from 
12 countries from Europe and North America and were ascertained through: 
RAD51C/D variant screening of families with multiple TOC or BC affected members 
(24 studies); and RAD51C/D variant screening of TOC or BC patients unselected for 
cancer family history (3 studies). One study included families ascertained through 
both schemes. Four studies provided data on all families screened for RAD51C or 
RAD51D variants, irrespective of the result (Supplementary Table 3). Participants 
provided informed consent in accordance with institutional-review-board policies and 
local practices. The list of study centres and ascertainment criteria are provided in 
Supplementary Table 3. 
Variants 
Pathogenic variants including frameshift, nonsense, canonical splice sites and 
large genomic deletions were considered in the analyses. Variants in the last exon 
were excluded. We estimated the population RAD51C and RAD51D variant using the 




Cancer inheritance patterns and observed genotypes in families were 
modelled using complex segregation analysis to estimate TOC and BC RRs 
simultaneously (8, 9) in the pedigree analysis software Mendel, version 3.3 (10).  
Family members were followed from birth until the age at first cancer diagnosis 
(excluding non-melanoma skin cancer), age at death, age at last follow-up, age at 
risk-reducing surgery (bilateral mastectomy in the BC analyses or bilateral salpingo-
oophorectomy in the TOC analyses if they occurred at least one year prior to cancer 
diagnosis), or age 80 years, whichever occurred first . Women diagnosed with a first 
TOC or BC were assumed to be affected at the age of diagnosis whilst women with 
any other type of first cancer diagnosis were censored at the age of diagnosis and 
were assumed as unaffected. Missing ages were inferred from other information 
(Supplementary Methods). Individuals with unknown disease status and no age 
information were censored at age 0.  
Each female was assumed to be at risk of developing TOC and BC assuming 
that the probability of developing each cancer was independent of one another 
conditional on genotype. We modelled the TOC and BC incidences so that they 
depend on the underlying assumed genetic effects (Supplementary Methods). Two 
main genetic models were fitted: a major-gene model that assumed all familial 
aggregation of TOC and BC to be due to RAD51C or RAD51D; and a major-gene 
plus polygenic component model that considered an additional residual familial 
component representing other unobserved genetic effects not due to RAD51C or 
RAD51D (11, 12) (Supplementary Methods). Models were fitted in which the log-
Relative Risk (logRR) for RAD51C/D pathogenic variant carriers relative to population 
incidences was assumed to be either constant across the whole age range; constant 
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for specific age groups; or a piecewise linear function of age (Supplementary 
Methods). We used country-, cohort- and population- age-specific incidences and 
constrained the overall cancer age-specific incidences over all assumed genetic 
effects to agree with the population age-specific incidences (12, 13) (Supplementary 
Methods). 
Since families were ascertained through different criteria across studies, we 
employed the “ascertainment assumption-free” approach to adjust for ascertainment 
by computing the pedigree likelihood conditional on all data relevant to the 
ascertainment (14-16) (Supplementary Methods). Non-informative families, for which 
no additional information was available beyond the data relevant to the 
ascertainment, were excluded from the analysis. 
The most parsimonious models were selected by comparing either the Akaike 
information criterion (AIC) for non-nested models, by selecting the model with the 
smaller AIC, or using the likelihood ratio test (LRT) for nested models. The hypothesis 
that the RR is 1.00 was assessed using a Wald test statistic. All statistical tests were 
two-sided. Statistical significance was considered as a P-value<0.05. 
Results 
Variants and families 
A total of 7,216 families eligible for pathogenic variant analysis were submitted 
to the coordinating centre, where 6,049 were identified through individuals with 
multiple relatives diagnosed with TOC or BC, and 1,167 were identified through 
women diagnosed with TOC or BC unselected for cancer family history.  After 
adjustment for ascertainment, 6,178 and 6,690 families were eligible for the RAD51C 
and RAD51D penetrance analysis respectively (Supplementary Tables 3-4). These 
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included 215 women with RAD51C pathogenic variants (137 were TOC and/or BC 
cases) from 125 families, and 92 women with RAD51D pathogenic variants (66 were 
TOC or BC cases) from 60 families (Table 1). Full lists of the RAD51C and RAD51D 
pathogenic variants in this dataset are summarized in Supplementary Table 5-6. The 
pathogenic variant population frequencies used in the segregation analysis model 
were estimated to be 0.00022 for RAD51C and 0.00026 for RAD51D based on 
42,325 cancer-free individuals from the UK Biobank exome sequencing data.  
Risk models 
The genetic models that included a residual polygenic/modifying familial 
component for TOC and BC provided better fits to the data than the major-gene 
models for both RAD51C and RAD51D (results for major gene models not shown). 
For RAD51C, using a constant RR with age, the AIC for the major gene model was 
4363 compared with 4346 for the BC polygenic model and with 4336 for the TOC 
polygenic model (Table 2). For RAD51D, the AIC for the major-gene model was 4187 
compared with 4178 for the BC polygenic model and with 4160 for the TOC polygenic 
model (Table 2). Therefore, we based all subsequent analyses on the major-gene 
plus polygenic component models.  
Tubo-ovarian carcinoma risk 
The estimated TOC RRs were 7.55 (95%CI: 5.60-10.19, p=5×10-40) for 
RAD51C and 7.60 (95%CI: 5.61-10.30, p=5×10-39) for RAD51D pathogenic variant 
carriers when RRs were assumed to be constant with age (Table 2).  When separate 
RRs were estimated for each age-decade, there was a suggestion that RRs 
increased with age until 60-69 years and then decreased for RAD51C pathogenic 
variant carriers. A similar pattern was seen for RAD51D pathogenic variant carriers 
but the RR peaked in the 50-59 age group (Table 2). These models provided a better 
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fit to the data than the models with a constant RR for both RAD51C (LRT-test, 
degrees of freedom (df)=4, p=0.04) and RAD51D (LRT, df=4, p=0.02). When we 
partitioned age into <50 years and ≥50, the estimated TOC RRs were higher for ages 
≥50 years for both RAD51C (RR=9.44, 95%CI:6.63-13.45 for ages≥50; RR=4.97, 
95%CI:2.75-8.97 for ages<50) and RAD51D pathogenic variant carriers (RR=10.56, 
95%CI:7.48-14.91 for ages≥50; RR=3.23, 95%CI:1.36-7.71 for ages<50). The model 
with separate RR parameters for each decade of age did not fit better than this two 
age-group model in either RAD51C (LRT, df=3, p=0.12) or RAD51D (LRT, df=3, 
p=0.51). To smooth the RR changes over age, we fitted models in which the logRR 
was assumed to be a piecewise linear function of age. For RAD51C, there was 
statistically significant evidence that the RR increases with age (p=0.004) from age 
30 to age 60 years and then decreases. Similarly for RAD51D, there was statistically 
significant evidence that the RR increases with age (p=0.002) from age 30 to age 58 
years and then decreases. The piecewise linear models were the most parsimonious 
with the lowest AIC (Table 2). Under these models, the estimated cumulative risks of 
developing TOC for a woman with a RAD51C pathogenic variant to age 50 years was 
1% (95% CI: 0.6-2%) and 11% (95% CI: 6-21%) to age 80 years; the corresponding 
cumulative TOC risks were 0.8% (95% CI: 0.5-2%) to age 50 and 13% (95% CI: 7-
23%) to age 80 for a woman with a  RAD51D pathogenic variant, assuming the UK 
incidences (Figure 1 and Table 3). The corresponding risks using USA population 
incidences are shown in Supplementary Table 7. 
Breast cancer risk 
The estimated BC RR was 1.99 (95%CI:1.39-2.85, p=1.55×10-4) for RAD51C 
and 1.83 (95%CI:1.24-2.72, p=0.002) for RAD51D pathogenic variant carriers when 
RR was constant with age (Table 2). When RRs varied by age-decade, for RAD51C, 
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the statistically significant association was restricted to ages 30-49, but this model 
did not fit better than the model with a constant RR (LRT, df=5, p=0.37).  When only 
two age groups were assumed, there was further evidence of higher BC RR in 
younger ages (20-49 years, RR=2.42, 95%CI:1.61-3.63) compared with age ≥50 
(RR=1.36, 95%CI:0.70-2.63), but the model with a constant RR remained the most 
parsimonious. For RAD51D, a “U” shape pattern was observed with higher RR 
estimates in ages 20-39 and 70-79 years (Table 2), but the model with constant RR 
remained the most parsimonious (LRT, df=4, p=0.59 comparing against the age-
specific RR model, Table 2). The estimated cumulative risks of developing BC to age 
50 were 4% (95%CI:3-6%) for RAD51C and 4% (95%CI 2-5%) for RAD51D 
pathogenic variant carriers and to age 80 were 21% (95%CI:15-29%) for RAD51C 
and 20% (95 CI:14-28%) for RAD51D pathogenic variant carriers assuming UK 
incidences (Figure 1 and Table 3; Supplementary Table 7 assuming USA 
incidences).    
Birth cohort and variant screening sensitivity 
We assessed whether the estimated risks vary by birth cohort by estimating 
separate RRs for different birth cohort groupings (Supplementary Table 8).  There 
was a suggestion of increasing BC risks with more recent birth cohort, but the 
differences were not statistically significant. Similarly, there were no statistically 
significant differences in the TOC RR estimates between cohort groupings for either 
RAD51C or RAD51D RRs.  We also assessed the impact on the results of assuming 
a reduced mutation screening sensitivity when including RAD51C/D test-negative 
families (Supplementary Methods). As the mutation screening sensitivity parameter 
decreased, the estimated TOC and BC RRs increased (Supplementary Table 9).  
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Predicted risks by family history 
The most parsimonious models included a residual familial polygenic 
component. Under this model, the risk of developing TOC or BC for RAD51C/D 
pathogenic variant differs by cancer family history. The predicted risk of developing 
TOC to age 80 years varies from 11% (95%CI:6-21%) for RAD51C and 13% 
(95%CI:7-23%) for RAD51D pathogenic variant carriers with no family history of TOC 
in first and second-degree relatives to 32% (95%CI:20-50%) for RAD51C and 36% 
(95%CI:23-53%) for RAD51D pathogenic variant carriers whose mother and sister 
developed TOC at age 50 years (Figure 2 and Supplementary Tables 10-11). 
Similarly, the predicted cumulative risk of developing BC to age 80 years varies from 
20% (95%CI:15-28%) for RAD51C and 19% (95%CI:13-27%) for RAD51D 
pathogenic variant carriers with an unaffected mother at age 50 years and unaffected 
maternal grandmother at age 70 years to 46% (95%CI: 6-56%) for RAD51C and 44% 
(95%CI:33-55%) for RAD51D pathogenic variant carriers with two first degree 
relatives diagnosed with. 
Discussion 
This is the largest family-based study to date to estimate age-specific relative 
and absolute TOC and BC risks for RAD51C and RAD51D pathogenic variant 
carriers, confirming that RAD51C and RAD51D pathogenic variants are associated 
with TOC and BC risks which vary by cancer-family history. 
Several case-control studies have estimated the association between 
RAD51C and RAD51D pathogenic variants and TOC (Supplementary Table 1). 
However, these studies had limited statistical power and the OR estimates, ranging 
from 3.4 to 15.8, were (Supplementary Table 1). The reported associations with BC 
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risk have been unclear with conflicting evidence (Supplementary Table 2. A 
complicating factor in interpreting the results from some BC case-control studies 
includes the fact that BC cases may have been selected on the basis of family history 
of both BC and TOC, which may confound the BC associations given the known TOC 
association; and publicly-available controls were often not closely matched to the 
case populations. In contrast, the present analysis considered the ascertainment 
process for each family separately and modelled the simultaneous associations with 
TOC and BC. In addition, family-based analyses closely control for population 
stratification since genetic background is shared within families (17, 18).  
For both RAD51C and RAD51D pathogenic variants the TOC incidence 
markedly increases and peaks around ages 58-60 years compared with the country- 
and cohort-specific population incidences. Even though this is the largest study to 
date, the age specific results were based on relatively small numbers in each age 
group. If this pattern is replicated by other studies this may have implications on the 
timing of risk-reducing interventions.  
We used variant frequencies estimated from the UK (RAD51C: 0.00022; 
RAD51D: 0.00026). These are similar to other frequency estimates. Following the 
same pathogenic variant selection criteria, the variant frequencies were estimated to 
be 0.00055 for RAD51C and 0.0003 for RAD51D using European non-Finnish non 
cancer gnomAD data and 0.0007 for RAD51C and 0.0004 for RAD51D from Song et 
al (7). Therefore, our results are unlikely to have been influenced by incorrect 
assumptions for the population variant frequencies.       
To maximise the number of families used in the analyses, for studies with data 
available for all families used in the mutation screening process, we used both 
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families in which pathogenic variants were detected and families without pathogenic 
variants, under the assumption that the mutation screening sensitivity is 100%. Our 
analyses which assumed reduced mutation screening sensitivity suggest that if this 
is substantially lower (~60%), the estimated risks may have been somewhat 
underestimated. The results were very similar to the main results for the most 
plausible values of 80-90%.    
Women diagnosed with cancer were censored at the age of risk-reducing 
surgery if the surgery occurred at least one year prior to cancer diagnosis. We 
repeated the analysis assuming women were censored at the age of risk-reducing 
surgery plus one year for both affected and unaffected. The results were almost 
identical to the main analysis (Supplementary Table 12) suggesting that this 
assumption in unlikely to have led to bias in the results due to unequal counting of 
person-time.  
The most parsimonious models incorporated a residual polygenic component, 
which also modifies the TOC and BC risk for pathogenic variant carriers. This 
indicates that other unobserved genetic or environmental risk factors shared in 
families may modify cancer risks for pathogenic variant carriers, consistent with 
results on other susceptibility genes e.g. BRCA1, BRCA2, PALB2 and CHEK2 (11, 
12, 19-23). These may include the combined effects of common genetic variants 
(polygenic risk score, PRS) identified through genome-wide association studies 
which have been shown to modify TOC and BC risks for pathogenic variant carriers 
in other genes (24, 25). The results presented here imply that cancer family history 
should be considered when counselling carriers with RAD51C/D pathogenic variants 
as it can lead to large differences in the cumulative TOC and BC and thus influence 
clinical management. For example, the cumulative risk of TOC to age 80 could be as 
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high as 20-23% for a woman with a RAD51C/D pathogenic variant if her mother 
developed TOC at age 55 (Figure 2 and Supplementary Table 10-11).  Similarly, a 
woman with a RAD51C/D pathogenic variant and a first degree relative diagnosed 
with BC at a young age would be classified as at “high-risk” (≥30%) of developing BC 
on the basis of the current NICE guidelines in the UK (26).  
The current study has several limitations. Although this is the largest study of 
its kind to date, we were not able to assess variations in risks by variant type or 
location. Similarly, the number of TOC/BC cases in some age groups remains small 
and age specific RR estimates are associated with large standard errors (Table 2). 
Previous studies have suggested that pathogenic variants in RAD51C or RAD51D 
may be more strongly associated with specific BC subtypes, in particular estrogen 
receptor negative or triple-negative BC (3, 4). No cancer subtype analysis were 
performed for either BC or TOC. To estimate subtype-specific associations in this 
study design requires tumour pathology data being available on all family members 
diagnosed with BC/TOC but these were not available. Nevertheless, our BC risk 
estimates will still be of clinical relevance as current screening or other interventions 
do not distinguish between the risks for different BC subtypes. The analysis was 
restricted to studies from Europe and North America. Further studies are needed 
when applying our findings to other populations. 
It has been recently suggested that risk-reducing salpingo-oophorectomy 
(RRSO) may be offered to women with lifetime risks of TOC of >4-5% (27, 28). The 
current cumulative risk estimates and associated confidence intervals place both 
RAD51C and RAD51D pathogenic variant carriers in the category of women for 
whom RRSO could be recommended for prevention. However, unlike BRCA1 
pathogenic variants this may only be warranted for women over the age 50, which 
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allows for women of childbearing age to complete their families. Although the average 
risk estimates of BC for RAD51C/RAD51D pathogenic variant carriers would place 
these women in the moderate risk category, in combination with family history of BC, 
the cumulative risks could be as high as 46% (Figure 2), which would place them in 
the high-risk category based on the NICE guidelines (26).  
In summary, we refined and provided age-specific TOC risk estimates for 
women with RAD51C and RAD51D pathogenic variants. We also confirmed that both 
RAD51C and RAD51D pathogenic variants confer a moderate risk of BC. Our results 
suggest that the RAD51C and RAD51D genes should be included in gene panel 
testing for TOC and BC to guide cancer surveillance and prevention. Incorporation of 
RAD51C and RAD51D into risk prediction models should be considered to facilitate 
stratified TOC and BC risk management.  
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Table 1 Summary of women by mutation, disease status and age among the families 
with RAD51C and RAD51D pathogenic variants. 
Age (years) 
Pathogenic variant carriers Tested non carriers Untested 




         
<20 1 0 0 1 0 0 88 0 1 
20-29 6 1 0 2 0 0 73 4 1 
30-39 18 21 2 12 1 0 128 15 6 
40-49 26 25 10 24 4 0 156 35 12 
50-59 14 16 27 11 3 0 143 30 21 
60-69 9 6 20 9 5 2 161 35 24 
70-80 4 4 6 3 1 0 368 15 15 
missing* 0 0 0 0 0 0 172 0 0 
Total† 78 73 65 62 14 2 1289 134 80 
RAD51D 
(N=935 from 60 
families) 
         
<20 1 0 0 2 0 0 26 0 0 
20-29 2 1 0 2 0 0 40 0 0 
30-39 7 7 2 6 0 0 54 7 4 
40-49 7 11 4 8 2 1 80 19 7 
50-59 7 8 17 8 0 0 85 28 19 
60-69 1 3 10 5 2 0 87 13 14 
70-80 1 0 3 0 0 0 192 7 5 
Missing* 0 0 0 0 0 0 120 0 0 
Total 26 30 36 31 4 1 684 74 49 
*Individuals with missing phenotype information were censored at age 0. 
†There  are 3 individuals with two cancers diagnosed at the same age and counted in 
both BC and TOC: one is RAD51C pathogenic variant carrier and the other two were 
untested for RAD51C. 




Table 2 Estimated tubo-ovarian carcinoma and breast cancer RR for RAD51C and RAD51D pathogenic variant carriers.  











RAD51C       
Tubo-ovarian carcinoma       
Age-constant model 30-79 7.55 (5.60-10.19) 5×10-40 
 
4335.8 — 
Age-specific model for each decade of age 30-39 2.85 (0.46-17.70) — 0.04 4334.0 — 
40-49 5.94 (3.09-11.43) — 
50-59 8.55 (5.10-14.33) — 
60-69 13.90 (8.45-22.88) — 
70-79 2.54 (0.53-12.27) — 
Age-specific model, separate parameters for 2 
age groups: [30,50),[50,80) 
30-49 4.97 (2.75-8.97) — 0.048 4333.8 — 
50-79 9.44 (6.63-13.45) — 
Piecewise linear model‡ 35 2.40 — 0.004 4328.6 Yes 
45 5.14 — 
55 11.02 — 
65 9.02 — 
75 2.82 — 
Breast cancer       
Age-constant model 20-79 1.99 (1.39-2.85) 1.55×10-4 
 
4346.4 Yes 
Age-specific model, separate parameters for 
each decade of age 
20-29 1.19 (0.09-16.12) — 0.37 4351.0 — 
30-39 3.25 (1.60-6.62) — 
40-49 2.50 (1.41-4.45) — 
50-59 0.96 (0.34-2.71) — 
60-69 1.54 (0.45-5.36) — 
70-79 2.57 (0.61-10.81) — 
Age-specific model, separate parameters for 2 
age groups: [20,50),[50,80) 
20-49 2.42 (1.61-3.63) — 0.12 4346.0 — 
50-79 1.36 (0.70-2.63) — 
RAD51D       
Tubo-ovarian carcinoma       
Age-constant model 30-79 7.60 (5.61-10.30) 5×10-39 
 
4160.0 — 
Age-specific model for each decade of age 30-39 3.60 (0.78-16.75) — 0.02 4155.8 — 
29 
 
40-49 3.19 (1.04-9.72) — 
50-59 12.54 (7.62-20.63) — 
60-69 10.60 (6.10-18.41) — 
70-79 4.94 (1.34-18.26) — 
Age-specific model, separate parameters for 2 
age groups: [30,50),[50,80) 
30-49 3.23 (1.36-7.71) — 0.002 4152.1 — 
50-79 10.56 (7.48-14.91) — 
Piecewise linear model§ 35 1.64 — 0.002 4151.6 Yes 
45 4.30 — 
55 11.29 — 
65 10.16 — 
75 5.77 — 
Breast cancer       
Age-constant model 20-79 1.83 (1.24-2.72) 0.0002 
 
4177.9 Yes 
Age-specific model, separate parameters for 
each decade of age except for 20-39 age group 
20-39 2.25 (1.25-4.04) — 0.59 4183.1 — 
40-49 1.46 (0.69-3.09) — 
50-59 1.56 (0.69-3.51) — 
60-69 1.63 (0.54-4.98) — 
70-79 4.19 (1.51-11.62) — 
Age-specific model, separate parameters for 2 
age groups: [20,50),[50,80) 
20-49 1.84 (1.12-3.02) — 1.00 4179.9 — 
50-79 1.83 (1.02-3.26) — 
*The p-values assessing the null hypothesis of RR=1.00 
†Likelihood ratio tests (LRT) comparing each model against the model with a constant RR.  
‡logRR(t)=a+b1(t-30) if t ∈ [30,60); logRR(t)=a+b1×30+b2(t-60) if t ∈ [60,80) where a=0.49 (95% CI: -0.80 to 1.78), b1=0.076 (95% CI: 
0.023 to 0.13), b2=-0.12 (95% CI: -0.23 to -0.0036)   
§logRR(t)=a+b1(t-30) if t ∈ [30,58); logRR(t)=a+b1×28+b2(t-58) if t ∈ [58,80) where a=0.010 (95% CI: -1.49 to 1.51), b1=0.097 (95% 




Table 3 Estimated age-specific cancer incidences and cumulative cancer risks for RAD51C and RAD51D pathogenic variant carriers 
Age (years) 
RAD51C pathogenic variant carriers RAD51D pathogenic variant carriers 
BC TOC BC TOC 
Estimated incidences per 1,000 person-years 
(95% Confidence Interval)* 
    
30 0.4 (0.2-0.5) 0.05 (0.01-0.2) 0.3 (0.2-0.5) 0.03 (0.007-0.1) 
40 2 (1-3) 0.3 (0.2-0.8) 2 (1-2) 0.3 (0.1-0.7) 
50 5 (3-6) 2 (1-3) 4 (3-6) 2 (1-3) 
60 6 (4-9) 7 (4-11) 6 (4-9) 6 (4-8) 
70 7 (5-10) 3 (1-8) 7 (4-10) 5 (2-9) 
79 8 (5-11) 1 (0.2-8) 7 (5-11) 3 (0.9-12) 
Estimated cumulative risks, %, (95% 
Confidence Interval)* 
    
30 0.1 (0.08-0.2) 0.02 (0.02-0.02) 0.1 (0.07-0.2) 0.02 (0.02-0.02) 
40 1 (0.7-1) 0.2 (0.08-0.4) 0.9 (0.6-1) 0.1 (0.06-0.3) 
50 4 (3-6) 1 (0.6-2) 4 (2-5) 0.8 (0.5-2) 
60 9 (6-12) 4 (3-7) 8 (6-12) 4 (3-7) 
70 15 (11-21) 9 (6-14) 14 (10-20) 9 (6-14) 
80 21 (15-29) 11 (6-21) 20 (14-28) 13 (7-23) 
*Assuming the UK population calendar and cohort specific incidences for an individual born between 1950-1959. Mortality is not 
accounted for absolute risk estimates. 




Figure 1 Estimated age-specific tubo-ovarian carcinoma and breast cancer 
cumulative risks in RAD51C and RAD51D pathogenic variant carriers. The 












Figure 2 Estimated tubo-ovarian carcinoma and breast cancer cumulative risks 






Variant frequencies  
We estimated the RAD51C and RAD51D pathogenic variant frequencies in the 
population using the UK Biobank exome sequencing dataset 
(http://www.ukbiobank.ac.uk). Specifically, among the 49,960 available subjects, we 
selected cancer-free individuals (either self-reported or medical records) and removed 
relatives up to second degree, leaving 42,325 individuals for the variant frequency 
estimation. The pathogenic variants within RAD51C and RAD51D were extracted. 
Variants in the last exon were excluded. The pathogenic variant frequencies were 
estimated and were used as input parameters in the segregation analysis. 
Missing age at cancer diagnosis 
Individuals with missing age at cancer diagnosis but other age information available 
were assumed to develop the corresponding cancer at the minimum available age. 
For those without any age information available, we assigned the age at cancer 
diagnosis to be the “average cancer-specific age at diagnosis” obtained from:  the 
family, within the study group and within the country, whichever was available in this 
order. A summary of the number of individuals with missing age is shown in 
Supplementary Table 13.  
Statistical models 
Two main genetic models were fitted: (1) a major-gene model that assumed all familial 
aggregation of tubo-ovarian carcinoma (TOC) and breast cancer (BC) to be due to 
RAD51C or RAD51D; and (2) a polygenic model that considered an additional residual 
familial component representing other unobserved genetic effects not due to RAD51C 
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or RAD51D (1, 2). Under each model, the cancer incidence for individual i at age t 
born in cohort k from country c was dependent on the underlying genetic effects though 
a model of the form 
𝜆𝑖(𝑡, 𝑘, 𝑐) = 𝜆0(𝑡, 𝑘, 𝑐) exp((𝑡)𝐺𝑖 +  𝑃𝑖), 
where 𝜆0(𝑡, 𝑘, 𝑐) is the baseline incidence for non-RAD51C/D carriers at age t for 
cohort k and country c, Gi is an indicator variable taking values 1 for RAD51C/D 
pathogenic variant carriers and 0 for non-carriers, and 𝑃𝑖 is the polygenic component 
which was set to 0 under the single-gene models and was assumed to be normally 
distributed with mean 0 and variance 𝜎𝑅
2 under the polygenic models (3, 4). (𝑡) is the 
log-risk ratio for RAD51C/D pathogenic variant relative to non-carriers. To ease 
interpretation, the models were parameterised in terms of the cancer-specific log-
relative risk (log-RR) for RAD51C and RAD51D pathogenic variant carriers relative to 






where iRAD51C/D+(t, k, c) denotes the average cancer incidence for RAD51C/D 
pathogenic variant carriers at age t born in cohort k from country c (over all polygenic 
effects) and ipop(t, k, c) denotes the population incidence at age t for cohort k and 
country c.  
We constrained the total genetic variance (𝜎𝑡𝑜𝑡𝑎𝑙
2 ), which was defined as the sum of 
the variance due to RAD51C/D pathogenic variant (𝜎𝐾
2) and the residual polygenic 
variance (𝜎𝑅
2 ), to agree with external estimates of the total polygenic variance. This 
was assumed be equal to 2.06 for TOC and 1.66 for BC, based on estimates from 
previously published segregation analyses (1, 5-7).   
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When the logRR for RAD51C/D pathogenic variant carriers relative to the population 
incidences was assumed to be a piecewise linear function of age, the logRR(t)  was 
modelled as: 
logRR((𝑡)) = {
𝑎 + 𝑏1(𝑡 − 30),                               𝑡 ∈ [30, 𝜏) 
𝑎 + 𝑏1(𝜏 − 30) + 𝑏2(𝑡 − 𝜏),        𝑡 ∈ [𝜏, 80)
 
where, t is the age,  𝜏 is the age-breakpoint where the slope changes to 𝑏2. We 
optimised 𝜏 by fitting a series of models in which 𝜏  took values from age 55 to 65 (the 
plausible age range from the age-specific logRR models). 
Cancer incidences 
Country- and cohort-specific population cancer incidences (Cancer incidence in five 
continents, http://ci5.iarc.fr/CI5plus/Default.aspx) were used here to take into account 
differences in incidences by study group, study location and changes in incidences 
over time. The overall cancer incidences were constrained over all assumed genetic 
effects in the model to agree with the population incidences (5). The reported 5-year 
interval constant incidences were smoothed using the locally weighted regression 
LOWESS approach (8, 9). A total of eight cohort-specific incidences (<1920, 1920-
1929, 1930-1939, 1940-1949, 1950-1959, 1960-1969, 1970-1979 and >1980) were 
used in the model by assuming each individual was born at the midpoint of each 
assumed cohort period (1915 for the first cohort and 1985 for the last cohort).  
Ascertainment adjustment 
We adjusted for ascertainment for each family separately by employing an 
assumption-free approach (10-12). We divided the data for each family into two parts 
depending on whether the data could be relevant to the ascertainment (F1) or not (F2). 
The conditional likelihood L=Pr(F1, F2)/Pr(F1) was then maximized, where Pr(F1, F2) 
is the probability of the observed data in the entire pedigree and Pr(F1) is the 
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probability of the observed data in the component relevant to the ascertainment. 
Specifically, for population-based families, F1 included the phenotype and genotype 
of the proband only. For families ascertained through multiple affected members, F1 
included the genotype of the proband and phenotypes of all the family members. For 
the families from the four studies that provided data irrespective of the variant 
screening result (ICR, UKFOCSS, UKFOCR, and SEARCH), the proband’s genotype 
was excluded from F1 as it did not form part of the ascertainment (Supplementary 
Table 4).  
Variant screening sensitivity 
Four studies (ICR, UKFOCSS, UKFOCR and SEARCH) provided data on all families 
screened for RAD51C or RAD51D variants, irrespective of the mutation search result. 
Details of these studies and methods have been published elsewhere (13-15). In these 
families only the proband was screened for RAD51C/D mutations. To maximise the 
number of informative families included in the analysis (after ascertainment 
adjustment), for these four studies, the analysis included also the families in which the 
proband was found not to carry a pathogenic variant in RAD51C or RAD51D and these 
probands were treated as non-carriers in the analyses. However, this assumes that 
the variant screening sensitivity, describing the probability of detecting a variant given 
it exists, is 100%, which may not be necessarily true given the variant screening was 
carried in research setting in those studies. In practice variant screening sensitivity 
could be lower and some of the non-carrier families may carry pathogenic variants in 
RAD51C or RAD51D. To assess the impact of a reduced variant screening sensitivity 
on the risk estimates we extended the models to allow for a reduced variant screening 




Supplementary Table 1 Previously published studies on tubo-ovarian carcinoma 
(TOC) risks associated with germline mutations in RAD51C and RAD51D 
 






OR (95% CI) 
Reference 




























































FH and 94 
selected for 
FH) 
0.00036 0.00018 5.2 (1.1-24) 12 (1.5-90) (15) 






HR (95% CI) 
Reference 
RAD51C RAD51D RAD51C RAD51D 





911 families with FH of 
BC/TOC 




*BC: breast cancer 
†TOC: tubo-ovarian carcinoma 
‡FH: family history  








Supplementary Table 2 Previously published studies on breast cancer risks 
associated with germline mutations in RAD51C and RAD51D 
 






OR (95% CI) 
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HR (95% CI) 
Reference 
RAD51C RAD51D RAD51C RAD51D 





911 families with FH of 
BC/TOC 




*FH: family history 
†BC: breast cancer 
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‡TOC: tubo-ovarian carcinoma 
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Supplementary Table 3 List of contributing study groups and number of families 
 
Study group 
Full name of 
study groups 








excluded from the 
analysis due to 
ascertainment 
 
Number of families  
eligible for inclusion in 
the analysis with 
pathogenic variants‡  
Reference 
RAD51C RAD51D fhx* pop† RAD51C RAD51D RAD51C RAD51D  



















7 1 8 0 3 1 4 0 
 




1 0 1 0 1 0 0 0 
 








Pública Galega de 
Medicina 
Xenómica 












Full name of 
study groups 








excluded from the 
analysis due to 
ascertainment 
 
Number of families  
eligible for inclusion in 
the analysis with 
pathogenic variants‡  
Reference 













0 3 3 0 0 1 0 2 (24) 








5354 (among these, 
4451 families were 
screened for RAD51C 
and 5026 families 
were screened for 
RAD51D) 






























1 2 0 3 0 0 1 2 (25) 
MCBCS   1 0 1 0 1 0 0 0  





1 0 1 0 0 0 1 0  




Full name of 
study groups 








excluded from the 
analysis due to 
ascertainment 
 
Number of families  
eligible for inclusion in 
the analysis with 
pathogenic variants‡  
Reference 









491 (among these, 486 
families were screened 
for RAD51C and 484 
families were screened 
for RAD51D) 



















1158 (among these, 
1151 families were 
screened for RAD51C 
and 1154 families were 
screened for RAD51D) 





















9 1 10 0 3 0 6 1  




1 0 1 0 1 0 0 0  
USC 
 University of 
South California 
2 2 4 0 0 1 2 1  
Total 
  














*fhx: family-based ascertainment 
†pop: population-based ascertainment 
‡For ICR, SEARCH and UKFOCSS/UKFOCR the cell contains the total number of families screened for RAD51C or RAD51D 
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Supplementary Table 4 Summary of types of ascertainment adjustment schemes 





F1: Data relevant to 
ascertainment 




(1) Phenotype of the 
proband 
(1) Phenotypes of all family 
members except the proband; 
(2) mutation status of all family 
members  
Others 
(1) Phenotype of the 
proband; (2) mutation 
status of the proband 
(1) Phenotypes of all family 
members except the proband; 
(2) mutation status of all family 




(1) All family 
phenotypes 
Mutation status of all family 
members  
Others 
(1) All family 
phenotypes; (2) 
mutation status of the 
proband 
Mutation status of all family 



















Supplementary Table 5 List of pathogenic variants in RAD51C among eligible 
families included in the analysis 
Variants HGVS 
(ref: ENST00000337432.9) 
Type Number of families 
c.158_160delinsTT frameshift variant 1 
c.158del frameshift variant 1 
c.181_182del frameshift variant 2 
c.186_187del frameshift variant 1 
c.216_220del frameshift variant 2 
c.224dup frameshift variant 6 
c.483_484insC frameshift variant 2 
c.498del frameshift variant 2 
c.501_502dup frameshift variant 1 
c.525dup frameshift variant 3 
c.622_623del frameshift variant 1 
c.651_652del frameshift variant 1 
c.704dup frameshift variant 1 
c.732del frameshift variant 4 
c.774del frameshift variant 3 
c.849_852del frameshift variant 1 
c.862del frameshift variant 3 
c.890del frameshift variant 1 
c.93del frameshift variant 14 
c.945dup frameshift variant 1 
c.966-?_c.1131+?del frameshift variant 1 
c.572-?_c.1131+?del frameshift variant 1 
c.706-?_c.1131+?del frameshift variant 12 
c.966-?_c.1026+?del frameshift variant 2 
c.706-?_c.837+?del in-frame large deletion 1 
c.145+1G>T intron splicing site variant 2 
c.146-4_146-2del intron splicing site variant 1 
c.404+2T>C intron splicing site variant 2 
c.571+1G>A intron splicing site variant 2 
c.572-1G>T intron splicing site variant 1 
c.705+1G>A intron splicing site variant 1 
c.706-1G>A intron splicing site variant 3 
c.706-2A>G intron splicing site variant 14 
c.837+1G>A intron splicing site variant 2 
c.905-2_905-1del intron splicing site variant 2 
c.905-2del intron splicing site variant 1 
c.397C>T nonsense variant 3 
c.502A>T nonsense variant 2 
c.577C>T nonsense variant 6 
c.664C>T nonsense variant 1 
c.701C>G nonsense variant 2 
c.955C>T nonsense variant 7 
c.97C>T nonsense variant 4 





Supplementary Table 6 List of pathogenic variants in RAD51D among eligible 
families included in the analysis 
Variants HGVS 
(ref: ENST00000345365.10) 
Type Number of families 
c.140_141insAA frameshift variant 1 
c.255_256insCTCCCAAAGTGCTAGG frameshift variant 1 
c.270_271dup frameshift variant 1 
c.363del frameshift variant 2 
c.416del frameshift variant 1 
c.480+1G>A frameshift variant 1 
c.564_567del frameshift variant 2 
c.564del frameshift variant 2 
c.623dup frameshift variant 1 
c.667_667+21del frameshift variant 1 
c.740_741dup frameshift variant 1 
c.748del frameshift variant 5 
c.83-?_577-?del frameshift variant 1 
c.145-?_263+?del frameshift variant 1 
c.451C>T nonsense variant 1 
c.478C>T nonsense variant 1 
c.547C>T nonsense variant 1 
c.556C>T nonsense variant 11 
c.620C>A nonsense variant 1 
c.649G>T; c.655C>T (cis) nonsense variant 1 
c.694C>T nonsense variant 4 
c.757C>T nonsense variant 2 
c.803G>A nonsense variant 3 
c.898C>T nonsense variant 4 
c.263+1G>A intron splicing site variant 1 
c.576+1G>A intron splicing site variant 5 
c.577-2A>G intron splicing site variant 2 
c.649_655delinsTGAGGTT intron splicing site variant 1 











Supplementary Table 7 Estimated age-specific cancer incidences and cumulative 
cancer risks for RAD51C and RAD51D pathogenic variant carriers in the USA. 
Age 
(years) 
Estimated incidences (per 1,000 person-years) for RAD51C and RAD51D 
pathogenic variant carriers (95% Confidence Interval)* 
RAD51C RAD51D 
BC TOC BC TOC 
30 0.4 (0.3-0.6) 0.06 (0.02-0.2) 0.4 (0.3-0.6) 0.04 (0.009-0.2) 
40 2 (1-3) 0.3 (0.1-0.7) 2 (1-3) 0.2 (0.1-0.6) 
50 4 (3-6) 1 (1-2) 4 (3-6) 1 (0.9-2) 
60 7 (5-9) 5 (3-8) 6 (4-9) 4 (3-6) 
70 9 (6-13) 2 (0.9-6) 8 (6-12) 3 (2-7) 
79 9 (6-13) 0.9 (0.1-6) 8 (6-12) 2 (0.6-9) 
Age 
(years) 
Estimated cumulative risks (%) for RAD51C and RAD51D pathogenic 
variant carriers by age (95% Confidence Interval)* 
RAD51C RAD51D 
BC TOC BC TOC 
30 0.1 (0.1-0.2) 0.04 (0.04-0.04) 0.1 (0.09-0.2) 0.04 (0.04-0.04) 
40 1 (0.8-2) 0.2 (0.09-0.4) 1 (0.7-2) 0.1 (0.07-0.4) 
50 4 (3-6) 0.9 (0.5-2) 4 (3-6) 0.8 (0.4-1) 
60 9 (6-13) 4 (2-6) 8 (6-12) 3 (2-6) 
70 16 (11-22) 7 (4-11) 15 (10-21) 7 (5-11) 
80 23 (17-31) 8 (5-17) 21 (15-30) 10 (6-18) 
*Assuming the USA population calendar and cohort specific incidences for an 
individual born between 1950-1959. Mortality is not accounted for absolute risk 
estimate 











Supplementary Table 8 Estimated relative risks (RRs) of tubo-ovarian carcinoma 
(TOC) and breast cancer (BC) for RAD51C and RAD51D pathogenic variant carriers 
by birth cohort 
Cancer Year of birth 
RAD51C RAD51D 
RR (95% CI) p-value* RR (95% CI) p-value* 
BC 
Before 1940 1 
0.15 
1 
0.57 1940-1959 2.47 (0.77-7.93) 1.43 (0.5-4.09) 
in 1960 or later 2.68 (0.81-8.84) 1.82 (0.57-5.81) 
TOC 
Before 1940 1 
0.43 
1 
0.75 1940-1959 1.19 (0.54-2.62) 1.17 (0.53-2.61) 
in 1960 or later 0.53 (0.13-2.16) 0.76 (0.23-2.56) 

















Supplementary Table 9 Estimated breast cancer (BC) and tubo-ovarian carcinoma 
(TOC) relative risks for RAD51C and RAD51D pathogenic variant carriers by different 
variant screening sensitivity parameters* 
Gene Cancer 
Assumed sensitivity of mutation screening 
0.9 0.8 0.7 0.6 
RAD51C 
BC 2.08 (1.46-2.98) 2.16 (1.51-3.10) 2.25 (1.57-3.24) 2.37 (1.64-3.43) 
TOC 8.29 (6.07-11.33) 8.94 (6.45-12.37) 9.75 (6.93-13.71) 10.86 (7.58-15.56) 
RAD51D 
BC 1.90 (1.28-2.82) 1.98 (1.33-2.94) 2.06 (1.38-3.07) 2.15 (1.44-3.22) 
TOC 8.22 (5.98-11.29) 8.86 (6.35-12.35) 9.72 (6.87-13.75) 10.89 (7.56-15.70) 

















Supplementary Table 10 Age-specific cumulative breast cancer (BC) risks (%) for 














BC at 35 
Mother and 





with BC at 50 
RAD51C 
30 0.1 (0.1-0.2) 0.1 (0.1-0.2) 0.2 (0.2-0.3) 0.3 (0.2-0.5) 0.2 (0.2-0.3) 
35 0.4 (0.3-0.6) 0.4 (0.3-0.5) 0.7 (0.5-1) 1 (0.8-2) 0.8 (0.6-1) 
40 1 (0.7-1) 1 (0.7-1) 2 (1-3) 3 (2-4) 2 (2-3) 
45 2 (2-3) 2 (2-3) 4 (3-6) 6 (4-8) 5 (3-6) 
50 4 (3-6) 4 (3-5) 7 (5-10) 11 (8-14) 8 (6-11) 
55 6 (4-9) 6 (4-9) 11 (8-16) 16 (12-22) 13 (9-17) 
60 9 (6-13) 9 (6-12) 16 (11-22) 23 (17-30) 18 (13-24) 
65 12 (9-17) 12 (8-16) 21 (15-28) 29 (22-38) 23 (17-31) 
70 15 (11-21) 15 (11-20) 26 (19-34) 36 (27-45) 29 (21-37) 
75 18 (13-25) 18 (13-24) 30 (22-39) 41 (32-51) 33 (25-43) 
80 21 (15-29) 21 (15-28) 34 (26-45) 46 (36-57) 38 (29-48) 
RAD51D 
30 0.1 (0.1-0.2) 0.1 (0.1-0.2) 0.2 (0.1-0.3) 0.3 (0.2-0.4) 0.2 (0.2-0.3) 
35 0.4 (0.2-0.5) 0.4 (0.2-0.5) 0.7 (0.5-1) 1 (0.7-2) 0.8 (0.5-1) 
40 0.9 (0.6-1) 0.9 (0.6-1) 2 (1-3) 3 (2-4) 2 (1-3) 
45 2 (1-3) 2 (1-3) 4 (3-5) 6 (4-8) 4 (3-6) 
50 4 (3-5) 4 (2-5) 7 (5-10) 10 (7-14) 8 (5-11) 
55 6 (4-9) 6 (4-8) 10 (7-15) 15 (11-21) 12 (8-17) 
60 8 (6-12) 8 (6-12) 15 (10-21) 21 (15-29) 16 (12-23) 
65 11 (8-16) 11 (7-15) 19 (14-27) 27 (20-36) 22 (15-30) 
70 14 (10-20) 14 (9-19) 24 (17-33) 33 (25-44) 27 (19-36) 
75 17 (12-24) 16 (11-23) 28 (20-38) 39 (29-50) 31 (23-41) 










Supplementary Table 11 Age-specific cumulative tubo-ovarian carcinoma (TOC) 














TOC at 55 
Mother and 
sister with 




with TOC at 50 
RAD51C 
35 0.1 (0-0.2) 0.1 (0-0.1) 0.1 (0.1-0.3) 0.2 (0.1-0.5) 0.2 (0.1-0.3) 
40 0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.3 (0.2-0.8) 0.6 (0.3-1) 0.4 (0.2-0.9) 
45 0.4 (0.2-0.9) 0.4 (0.2-0.9) 0.8 (0.4-2) 2 (0.7-3) 1 (0.5-2) 
50 1 (0.6-2) 1 (0.6-2) 2 (1-4) 4 (2-6) 2 (1-4) 
55 2 (1-4) 2 (1-3) 4 (3-7) 7 (5-11) 5 (3-8) 
60 4 (3-7) 4 (3-7) 9 (6-12) 14 (10-20) 10 (7-15) 
65 7 (5-11) 7 (5-11) 14 (9-20) 22 (16-31) 16 (11-23) 
70 9 (6-15) 9 (6-14) 17 (11-25) 27 (19-38) 20 (13-29) 
75 10 (6-18) 10 (6-18) 19 (12-30) 30 (20-45) 22 (14-35) 
80 11 (6-21) 11 (6-21) 20 (12-35) 32 (20-51) 24 (14-40) 
RAD51D 
35 0 (0-0.1) 0 (0-0.1) 0.1 (0.1-0.2) 0.2 (0.1-0.4) 0.1 (0.1-0.3) 
40 0.1 (0.1-0.3) 0.1 (0.1-0.3) 0.2 (0.1-0.6) 0.4 (0.2-1) 0.3 (0.1-0.8) 
45 0.3 (0.2-0.8) 0.3 (0.2-0.8) 0.6 (0.3-2) 1 (0.5-3) 0.8 (0.4-2) 
50 0.8 (0.5-2) 0.8 (0.5-2) 2 (0.9-3) 3 (2-5) 2 (1-4) 
55 2 (1-3) 2 (1-3) 4 (3-6) 7 (4-10) 5 (3-7) 
60 4 (3-7) 4 (3-7) 8 (6-12) 14 (9-20) 10 (7-15) 
65 7 (5-11) 7 (5-10) 13 (9-19) 22 (15-30) 16 (11-22) 
70 9 (6-14) 9 (6-14) 17 (12-25) 28 (19-38) 20 (14-29) 
75 11 (7-19) 11 (7-18) 20 (13-31) 32 (23-46) 24 (16-36) 










Supplementary Table 12 Estimated tubo-ovarian carcinoma (TOC) and breast 
cancer (BC) RR for RAD51C and RAD51D pathogenic variant carriers under the 
best fitting models in the main text assuming censoring for risk-reducing surgery 
occurs one year after surgery for both affected and unaffected*. 
*There was only 1 unaffected woman in families with RAD51D pathogenic variants 
censored at risk-reducing bilateral mastectomy. The number of unaffected women who 
had undergone risk-reducing salpingo-oophorectomy were: 8 among the families with 
RAD51C pathogenic variants, and 5 among the families with RAD51D pathogenic 
variants.   
†logRR(t)=a+b1(t-30) if t ∈ [30,60); logRR(t)=a+b1×30+b2(t-60) if t ∈ [60,80) where 
a=0.49 (95% CI: -0.75 to 1.74), b1=0.076 (95% CI: 0.025 to 0.13), b2=-0.12 (95% CI: -
0.23 to -0.0043)   
‡logRR(t)=a+b1(t-30) if t ∈ [30,58); logRR(t)=a+b1×28+b2(t-58) if t ∈ [58,80) where 
a=0.011 (95% CI: -1.52 to 1.55), b1=0.097 (95% CI: 0.033 to 0.16), b2=-0.057 (95% 
CI: -0.13 to 0.016)   
 












BC Age-constant model 20-79 1.99 (1.39-2.85) 4346.5 
RAD51D 







BC Age-constant model 20-79 1.83 (1.24-2.72) 4178.0 
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Supplementary Table 13 A summary of the number of individuals with missing age 









ages at event 
(%) 
Number of individuals with missing ages at each 










the mean event 
age within the 




15850 2378 (15%) 1426 (9%) 871 (5.5%) 81 (0.5%) 
Ovarian 
cancer 




6172 1551 (25.13%) 
1014 
(16.4%) 
277 (4.5%) 260 (4.2%) 
Bilateral 
mastectomy 
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